Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Type:
Application
Filed:
May 29, 2014
Publication date:
March 12, 2015
Applicant:
Bristol-Myers Squibb Company
Inventors:
Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
Abstract: The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.
Abstract: Reagents are disclosed for chemoselective tagging of methionine residues in peptides and polypeptides, subsequent bioorthogonal tag functionalization, and cleavage of the tags when desired to regenerate unmodified samples. This method compliments other peptide tagging strategies and adds capability for tag removal, which may be useful for release of therapeutic peptides from a carrier, or release of tagged protein digests from solid supports.
Type:
Application
Filed:
March 26, 2013
Publication date:
February 26, 2015
Applicant:
The Regents of the University of California
Abstract: The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.
Type:
Grant
Filed:
September 9, 2010
Date of Patent:
February 24, 2015
Assignees:
Dompe S.p.A., Geymonat S.p.A.
Inventors:
Gaetano D'Anniballe, Franck Martin, Giuseppe Salvia
Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
Type:
Grant
Filed:
April 10, 2012
Date of Patent:
February 24, 2015
Assignee:
City of Hope
Inventors:
John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
Abstract: The present invention, in some embodiments thereof, relates to material science in general, and, more particularly, to sequence variants of Stable Protein 1 (SP1), to uses thereof, for binding of carbon nanotubes, production of composite polymers and polymer materials, such as fabrics, based on SP1-polypeptide-carbon nanotube-complexes, and the use thereof for enhancing conductivity in tire.
Type:
Grant
Filed:
August 26, 2010
Date of Patent:
February 17, 2015
Assignee:
Fulcrum S.P. Materials Ltd.
Inventors:
Amnon Wolf, Nimrod Litvak, Elena Grimberg, Galit Cohen, Arnon Heyman, Izhar Medalsy, Danny Porath, Oded Shoseyov, Asa Eitan
Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
Type:
Application
Filed:
November 28, 2012
Publication date:
February 12, 2015
Inventors:
Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Michal Szymanik, Anna Maria Pieczykolan, Bartlomiej Maciej Zerek, Piotr Rózga, Albert Robert Jaworski, Malgorzata Izabela Teska-Kaminska
Abstract: Identification and use of proteins fluorescently labeled and that undergo a change in fluorescence index upon binding bilirubin are described. Probes are disclosed which are labeled at a cysteine or lysine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for determination of unbound bilirubin levels in a fluid sample.
Type:
Application
Filed:
August 24, 2012
Publication date:
February 12, 2015
Inventors:
Alan Marc Kleinfeld, Andrew Henry Huber, James Patrick Kampf, Thomas Kwan, Baolong Zhu
Abstract: Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-? type II receptor (T?P?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-? type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-? type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-? type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-? isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-? isoforms, but not other ligands of the TGF-? superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs).
Type:
Application
Filed:
March 28, 2013
Publication date:
February 12, 2015
Inventors:
Hinck Andrew, Luzhen Sun, Christian Zwieb
Abstract: The present Invention relates to the monitoring of biological substances, such as non-invasive monitoring of such substances in animal, for examples biomarkers and metabolites. Specifically, the invention further relates to such monitoring using rare earth tagged marker compounds. The invention further relates to such monitoring using laser spectroscopy or Raman spectroscopy. The invention further relates to the use of such monitoring in disease states, such as stroke, neurological disorders and cardiovascular disorders.
Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.
Type:
Application
Filed:
October 3, 2014
Publication date:
January 29, 2015
Applicant:
CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Alex Kentsis, Hanno Steen, Richard Bachur
Abstract: The disclosure relates to milk protein nanoparticles produced according to a polymerization method in which at least one protein, which is obtained from milk and which can be thermally plasticized, is plasticized using a plasticizing agent, such as for example, water or glycerol at temperatures between room temperature and 140° C., subjected to mechanical stress and subsequently retreated, for example, in the top down or bottom up method to form nanoparticles.
Abstract: The present invention relates in a first aspect to a method of coating surfaces of substrates with a lattice-like structure. In particular, the present invention relates to an in vitro method of coating surfaces by binding of epsin or a fragment thereof on the surface and, thereafter, binding of a compound forming the lattice like structure, in particular, binding of the clathrin heavy chain, to the epsin bound on the surface, thus, obtaining a coated substrate having a lattice like structure on the surface. In another aspect, the present invention relates to an in vitro method of producing nanometer-sized liposomes having a clathrin structure on its surface. In addition, substrates, like elements or devices, with coated surfaces having a lattice-like structure on the surface are provided obtainable by a method according to the present invention.
Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
Type:
Application
Filed:
February 22, 2013
Publication date:
January 15, 2015
Applicant:
The Trustees of the University of Pennsylvania
Inventors:
Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
Abstract: The invention provides novel chemical entities based on sugar alcohols. These new chemical entities are biocompatible and biodegradable. The molecules can be made in a single and pure form. The molecular weights of these molecules range from small (<1000 Da) to large (1000-120,000 Da). The sugar alcohol-based molecules can have functional groups throughout the molecule for crosslinking compounds, such as the preparation of antibody-drug conjugates, or to facilitate the delivery of therapeutic proteins, peptides, siRNA, and chemotherapeutic drugs. Also provided are new conjugate entities prepared through sugar alcohol molecules. Methods of synthesizing sugar alcohol-based molecules and conjugates are also within the scope of the invention.
Abstract: Disclosed are pharmaceutical and synergistic compositions comprising human recombinant alpha-fetoprotein expressed in eucaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.
Type:
Grant
Filed:
October 22, 2010
Date of Patent:
January 13, 2015
Inventors:
Elena Dudich, Lydia Semenkova, Igor Dudich, Eduard Tatulov
Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.
Type:
Grant
Filed:
September 29, 2010
Date of Patent:
January 13, 2015
Assignee:
Bolder Biotechnology, Inc.
Inventors:
Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
Abstract: A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor.
Type:
Grant
Filed:
October 15, 2008
Date of Patent:
January 13, 2015
Assignee:
The Regents of the University of California
Inventors:
Leonard H. Rome, Valerie A. Kickhoefer, Raval-Fernandes Sujna, Phoebe L. Stewart
Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
Type:
Grant
Filed:
June 24, 2014
Date of Patent:
January 13, 2015
Assignee:
Lipoxen Technologies Limited
Inventors:
Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
Abstract: Quantitation of analytes, including but not limited to peptides, polypeptides, and proteins, in mass spectrometry using a labeled peptide coupled to a reporter, and a universal reporter.
Type:
Grant
Filed:
July 7, 2011
Date of Patent:
January 13, 2015
Assignee:
Thermo Fisher Scientific GmbH
Inventors:
Joel Louette, John Charles Rogers, Scott M. Peterman, Bruno Domon, Elodie Duriez
Abstract: Methods and systems for creating a genetic construct, a protein, and a polymer comprising a domain swapping module. A domain swapping module is a fusion protein in which a lever protein, which has a long amino (N) to carboxy (C) terminal distance, is inserted into a surface loop of an assembler protein, thereby stretching the assembler protein and splitting it into two fragments held apart by the lever so that they cannot rejoin. If the assembler protein is split at the proper location, the fragments will recombine with their respective counterparts from either one or more different—but similarly-split—assembler proteins.
Type:
Application
Filed:
December 27, 2012
Publication date:
January 8, 2015
Applicant:
The Research Foundation For The State University Of New York
Inventors:
Stewart Loh, Jeung-hio Ha, Diana Mitrea
Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.
Type:
Grant
Filed:
December 11, 2009
Date of Patent:
January 6, 2015
Assignee:
Korea Advanced Institute of Science and Technology (KAIST)
Inventors:
Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
Abstract: The present invention pertains to an affinity tag system for the immobilisation and/or purification of molecules such as biological or organic molecules. The invention provides EF-hand subdomains of calcium binding proteins, such as calbindin D9k, as affinity tags and affinity ligands for immobilising, detecting and/or for purifying molecules, particularly proteins. Also provided are methods utilising the affinity tag system of the invention, affinity matrices comprising EF-hand subdomain affinity ligands and fusion proteins comprising EF-hand subdomain affinity tags.
Type:
Application
Filed:
January 7, 2013
Publication date:
January 1, 2015
Applicant:
UNIVERSITY COLLEGE DUBLIN
Inventors:
David O'Connell, Sara Linse, Eva Thulin, Alejandro Merino
Abstract: The present invention is generally directed to functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention provides a graphene substrate. The substrate comprises edge and non-edge regions, and organic or inorganic molecules are bound to the edge regions of the substrate. The organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm.
Type:
Application
Filed:
May 23, 2014
Publication date:
January 1, 2015
Applicant:
NANOTECH BIOMACHINES, INC.
Inventors:
Jeffrey Alan McKinney, William Emerson Matinez
Abstract: The invention relates to a polypeptide comprising an amino acid having a norbornene group. Suitably said norbornene group is present as an amino acid residue of a norbornene lysine. The invention also relates to a method of producing a polypeptide comprising a norbornene group, said method comprising genetically incorporating an amino acid comprising a norbornene group into a polypeptide. The polypeptide comprising the norbornene group can be specifically labelled by inverse electron demand Diels-Alder reaction with a tetrazine compound.
Abstract: The invention relates to growth-inhibited hydroxyapatite for improving bone healing. It differs from the apatites employed to date in that it releases calcium ions and phosphate ions in physiological solutions, which, unlike traditional hydroxyapatites, it does not bind. It thereby promotes bone regeneration and bone growth. The growth-inhibited hydroxyapatite contains in agglomerates of prestructured collagen templates on which hydroxyapatite crystals with a crystallite growth of below its critical nucleus radius are formed epitactically. It is prepared by the steps a) mineralization of prestructured collagen templates in supersaturated Ca- and phosphate-ion-containing solutions, where the prestructured collagen templates are capable of diffusion and/or migration, so that HAP crystallites grow epitactically on the collagen templates and the collagen templates grown together with HAP crystallites agglomerate due to their capability of diffusion and/or migration, b) separating off the agglomerates.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
December 23, 2014
Assignee:
Technische Universität Dresden
Inventors:
Sascha Heinemann, Christiane Heinemann, Hartmut Worch, Thomas Hanke, Wolfgang Pompe
Abstract: The present invention provides a double-stranded RNA structure, which comprises a polymer compound covalently bonded to a double-helix oligo RNA useful for the treatment of diseases, particularly cancer, in order to enhance the delivery of the double-helix oligo RNA, and further comprises a target-specific ligand bonded thereto, a preparation method thereof, and a technique of delivering the double-helix oligo RNA in a target-specific manner using the RNA structure. A nanoparticle composed of the ligand-bonded double-helix oligo RNA structures can efficiently deliver the double-helix oligo RNA to a target, and thus can exhibit the activity of the double-helix oligo RNA even when the double-helix oligo RNA is administered at a relatively low concentration. Also, it can prevent the non-specific delivery of the double-helix oligo RNA into other organs and cells.
Type:
Application
Filed:
December 14, 2012
Publication date:
December 18, 2014
Inventors:
Jeiwook Chae, Boram Han, Han-na Kim, Han Oh Park, Pyoung Oh Yoon, Sun Gi Kim, Kwang-Ju Jung, Taewoo Kwon, Jong Deok Choi, Sam Young Lee, Eun-Jung Jung
Abstract: The present invention relates to the novel compound classes of dendritic polyglycerol sulfates and sulfonates as well as to their production and use for the treatment of diseases, particularly inflammatory diseases, and to their use as selectin inhibitors and selectin indicators. The dendritic polyglycerol sulfates and sulfonates are also suitable for imaging diagnostics, particularly with respect to inflammatory diseases.
Type:
Application
Filed:
August 26, 2014
Publication date:
December 11, 2014
Applicant:
FREIE UNIVERSITAT BERLIN
Inventors:
Rainer HAAG, Jens DERNEDDE, Rudolf TAUBER, Gesche BERNHARD, Sven ENDERS, Heidemarie WEINHART, Arne VON BONIN, Ulrich ZÜGEL, Holger TÜRK
Abstract: Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.
Type:
Application
Filed:
December 20, 2012
Publication date:
December 11, 2014
Applicant:
NOVO NORDISK A/S
Inventors:
Caspar Christensen, Michael Raunjær, Rune Severinsen, Jens C. Norrild
Abstract: A method for immobilizing an amino-containing material to a substrate is described. The method involves providing a tethering compound with two reactive groups: a substrate reactive group and a fluoroalkoxycarbonyl group. The method further involves preparing a substrate-attached tethering group by reacting the substrate reactive group of the tethering compound with a complementary functional group on the surface of a substrate. The substrate-attached tethering group has a fluoroalkoxycarbonyl group that can be reacted with an amino-containing material to form an immobilization group that connects the amino-containing material to the substrate.
Type:
Grant
Filed:
September 17, 2007
Date of Patent:
December 9, 2014
Assignee:
3M Innovative Properties Company
Inventors:
Karl E. Benson, Charles M. Leir, George G. I. Moore, Rahul R. Shah
Abstract: A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight turn containing a sequence of four to about seven amino acid residues in which at least two amino acid side chains extend on the same side of the tight turn and are within less than about 7 ? of each other. The chimeric therapeutic polypeptide has the sequon Aro-(Xxx)n-(Zzz)p-Asn-Yyy-Thr/Ser (SEQ ID NO:001) within that tight turn sequence such that the side chains of the Aro, Asn and Thr/Ser amino acid residues project on the same side of the turn and are within less than about 7 ? of each other. That sequon is absent from the pre-existing therapeutic polypeptide.
Type:
Grant
Filed:
August 2, 2012
Date of Patent:
December 9, 2014
Assignee:
The Scripps Research Institute
Inventors:
Jeffery W. Kelly, Joshua L. Price, Elizabeth K. Culyba, Evan T. Powers
Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.
Abstract: Disclosed are methods and compositions for treating cancer that involved an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of Hsp-27.
Abstract: The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications.
Abstract: The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.
Type:
Grant
Filed:
March 18, 2010
Date of Patent:
November 25, 2014
Assignee:
Hanmi Science Co., Ltd
Inventors:
Dae Hae Song, Jae Hee Shin, Jae Min Lee, Young Kyung Park, Se Chang Kwon, Gwan Sun Lee
Abstract: The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylooccus aureus Protein A (SpA), as well as methods of using the same.
Type:
Grant
Filed:
June 6, 2014
Date of Patent:
November 25, 2014
Assignee:
EMD Millipore Corporation
Inventors:
Shari Spector, Robert Smith, Joe Orlando, Nanying Bian
Abstract: A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune response against a plurality of avian influenza virus subtypes in a subject, comprising delivering the DNA vaccine or the DNA vaccine composition to tissue of the subject is also provided.
Abstract: The invention is a method for the purification of mono-PEGylated erythropoietin using two cation exchange chromatography steps wherein the same type of cation exchange material is used in both cation exchange chromatography steps and a method for producing a mono-PEGylated erythropoietin in substantially homogeneous form.
Type:
Grant
Filed:
January 24, 2011
Date of Patent:
November 18, 2014
Assignee:
Hoffman-La Roche Inc.
Inventors:
Josef Burg, Klaus Reichert, Axel Schroth, Hartmut Schurig, Axel Wessner
Abstract: The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis.
Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
Abstract: The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant.
Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.
Abstract: The present invention relates to a molecule capable of binding to adrenocorticotropic hormone (ACTH) with high affinity. The present invention also relates to use of the molecule for detection and/or purification of ACTH.
Abstract: The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Type:
Application
Filed:
January 15, 2014
Publication date:
October 30, 2014
Applicant:
Aileron Therapeutics, Inc.
Inventors:
Huw M. Nash, Rosanna Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata, Vincent Guerlavais, Matthew Iadanza
Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.
Type:
Application
Filed:
April 17, 2014
Publication date:
October 23, 2014
Applicant:
Heptares Therapeutics Limited
Inventors:
Malcolm Peter Weir, Fiona Hamilton Marshall